Literature DB >> 10362017

FGF9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells.

D Giri1, F Ropiquet, M Ittmann.   

Abstract

Polypeptide growth factors, including members of the fibroblast growth factor (FGF) family, play an important role in the growth and maintenance of the normal prostate. We have found that FGF9 is expressed at high levels in the normal peripheral and transition zone of the human prostate. Analysis of FGF9 production by primary cultures of prostatic epithelial and stromal cells has shown that FGF9 is produced and secreted by the prostatic stromal cells. Neither of these processes appears to be modulated by androgens. Production of FGF9 by stromal cells in vivo was confirmed by immunohistochemistry. FGF9 is a potent mitogen for both prostatic epithelial and stromal cells in culture and is a more potent mitogen for these cells than either FGF2 or FGF7, two other FGFs expressed in the human prostate. FGF9 is an abundant secreted growth factor that can act as both a paracrine mitogen for epithelial cells and an autocrine mitogen for stromal cells. Western blot analysis of tissue extracts from the normal and hyperplastic transition zone shows that FGF9 is present at two to threefold higher levels in the hyperplastic transition zone. Overexpression of this paracrine and autocrine growth factor may play an important role in the epithelial and stromal proliferation in benign prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10362017     DOI: 10.1002/(SICI)1097-4652(199907)180:1<53::AID-JCP6>3.0.CO;2-P

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  21 in total

1.  Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia.

Authors:  D Giri; M Ittmann
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 2.  Cellular signaling by fibroblast growth factors (FGFs) and their receptors (FGFRs) in male reproduction.

Authors:  Leanne M Cotton; Moira K O'Bryan; Barry T Hinton
Journal:  Endocr Rev       Date:  2008-01-23       Impact factor: 19.871

3.  Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts.

Authors:  Shengqiang Yu; Chiuan-Ren Yeh; Yuanjie Niu; Hong-Chiang Chang; Yu-Chieh Tsai; Harold L Moses; Chih-Rong Shyr; Chawnshang Chang; Shuyuan Yeh
Journal:  Prostate       Date:  2011-07-07       Impact factor: 4.104

4.  Regulation of Receptor Binding Specificity of FGF9 by an Autoinhibitory Homodimerization.

Authors:  Yang Liu; Jinghong Ma; Andrew Beenken; Lakshmi Srinivasan; Anna V Eliseenkova; Moosa Mohammadi
Journal:  Structure       Date:  2017-07-27       Impact factor: 5.006

5.  Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.

Authors:  B Kwabi-Addo; D Giri; K Schmidt; K Podsypanina; R Parsons; N Greenberg; M Ittmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

6.  Interleukin-6 is an autocrine growth factor in human prostate cancer.

Authors:  D Giri; M Ozen; M Ittmann
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

7.  Prostaglandin E2 induces fibroblast growth factor 9 via EP3-dependent protein kinase Cdelta and Elk-1 signaling.

Authors:  Pei-Chin Chuang; H Sunny Sun; Tsung-Ming Chen; Shaw-Jenq Tsai
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

8.  Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia.

Authors:  D Giri; M Ittmann
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

Review 9.  Growth factors in benign prostatic hyperplasia: basic science implications.

Authors:  M Scott Lucia; James R Lambert
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

10.  Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.

Authors:  Zhi Gang Li; Paul Mathew; Jun Yang; Michael W Starbuck; Amado J Zurita; Jie Liu; Charles Sikes; Asha S Multani; Eleni Efstathiou; Adriana Lopez; Jing Wang; Tina V Fanning; Victor G Prieto; Vikas Kundra; Elba S Vazquez; Patricia Troncoso; Austin K Raymond; Christopher J Logothetis; Sue-Hwa Lin; Sankar Maity; Nora M Navone
Journal:  J Clin Invest       Date:  2008-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.